Sameer Shahid Amin, Hussnain Abbas, Amjad Akram.
Diabetic macular oedema and role of intra viteral Triamcinolone acetonide
Pak Armed Forces Med J Sep 2007;57(3):211-5.
Military Hospital Rawalpindi

Aims: The aim of this study was to determine efficiency of intravitreal injection of triamcinolone (IVT) in diffuse macular edema secondary to diabetes mellitus. Methods: Twenty eight eyes of 28 patients who fulfilled the inclusion criteria were selected for the study. Patients had a full ophthalmic examination carried out. Injection triamcinolone acetonide (Kenalog) was given intravitreally with full aseptic measures patients were followed up at selected intervals of time. Results: At one month post injection interval 54% patients showed improvement in visual acuity. Three months post injection 43% patients maintained improvement in visual acuity. At six months post injections 18% maintained improvement while 43% showed no change and 14% showed deterioration of vision. Conclusion: We conclude that IVT has a favorable outcome in significant number of patients and may be an alternative to laser photocoagulation in diffuse macular edema secondary to diabetes mellitus.

Category: Eye
Keywords: Diabetic Macular Edema. Diabetic Retinopathy. Triamcinolon. Intraocular Pressure. Endophthalmitis.

Click here for Full Text Article

This article has been viewed 39 times


Download in Citation Manager - Print - Email - PakMediNet Member Services

Submit your Research Synopsis for Free Expert analysis - Search- Feedback - Drug Index

USER COMMENTS

No Comments yet posted for this article

POST YOUR COMMENTS HERE

Your USERNAME (login)
Your PASSWORD
Your Comments

Sponsored Link:
King Fahd University of Petroleum & Minerals


Journal Index - Specialty Index - Authors Index - Keywords Index - Research Synopsis - PakMediNet Drug Index
About us - Terms and Conditions - Contributors - Contact Us - Member Services

© All rights reserved and Copyright protected
No Part of Website is allowed to be copied without prior permission. Hosted by PakCyber (R).